PI3K/AKT/mTOR Dysregulation and Reprogramming Metabolic Pathways in Renal Cancer: Crosstalk with the VHL/HIF Axis
Renal cancer is characterized by overexpression of growth factors; epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), and insulin growth factor (IGF) that will induce the activation of the phosphatidyl-3-kinase-protein-kinase B-mammalian target of rapamycin (PI3K/AKT/mTOR) and RAS/MEK/ERK (RAS/mitogen-activated protein kinase/extracellular signal-regulated kinase). Further, this molecular signaling pathway inhibits the Von Hippel-Lindau (VHL) gene leading to the activation of hypoxia-inducible factors (HIFs) involved in renal cancer-reprogramming metabolism. Therefore, regarding glucose metabolism, this malignancy has increased glycolysis, glycogenolysis, pentose phosphate pathway (PPP), and increased tricarboxylic acid cycle (TCA), leading to lactate, pyruvate, NADPH, ribose-5-phosphate, malate, succinate, citrate, and acetyl-CoA accumulation. Additionally, the RAS/MEK/ERK signaling pathway promotes glycolysis and TCA. The compounds that resulted from altering glucose metabolism are involved in glutathione (GSH) regeneration, lipids, nucleotides, and amino acids (AA) biosynthesis. Fatty acids (FA) are used to produce energy by β-oxidation. Lipid metabolism alterations also include synthesis of FA, TAG (triacylglycerols), cholesterol, ceramides, sphingolipids, and phosphatidylcoline/phosphatidylethanolamine. Amino acids such as glutamine can suffer several modifications forming glutamate, α-ketoglutarate, and aspartate. The intermediates together with increased Tyr (tyrosine) and decreased Arg (arginine) and Trp (tryptophan) will be used by renal cancer cells for the synthesis of new AA, nucleotides, FA, citrate, oxaloacetate (OAA), and pyrimidine bases. All these compounds that result from the altered pathway lead to cancer cell survival, aggressiveness, and metastasis. These characteristics of malignant tumors are also promoted by cyclin D1 deregulation produced by mTORC1 by activating S6K and 4E-BP1. + represents activation; − means inhibited